Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2016

View Archived Issues

Alectos receives orphan drug designation for MK-8719

First-in-human results for nesvacumab in patients with advanced solid tumors

US Phytotherapy demonstrates dengue virus inhibition in preliminary cell culture studies

COMP as a novel prognostic biomarker in breast cancer

FDA grants orphan drug designation to DelMar's VAL-083

Roche patents beta-secretase 1 inhibitors

Lead Discovery Siena discloses guanidine derivatives

Merck & Co. reports TrK-A inhibitors

NITD-008 and galidesivir improve survival and reduce viremia in AG129 mouse model of ZIKV infection

BioMarin's BMN-250 begins phase I/II trial, awarded European orphan drug designation for MPS IIIB

Repatha becomes available in Japan

Positive interim data from phase II trial of KRN-23 as treatment of tumor-induced osteomalacia

AbbVie and CytomX collaborate on Probody drug conjugate targeting CD71

Galapagos reports 20-week phase II results for filgotinib in Crohn's disease

Sitagliptin is not beneficial in nonalcoholic fatty liver disease study

TapImmune begins phase II trial for cancer vaccine TPIV-200

AstraZeneca to transform drug discovery and development through new integrated genomics initiative

Deutetrabenazine exhibits positive effects on tics in adolescents with Tourette syndrome

Achaogen awarded contract option by NIAID to support LpxC inhibitor research

Opthea provides update on phase I trial for OPT-302

FDA gives orphan drug designation to cannabidiol for TSC

SFARI launches SPARK autism research study

Janssen files for Japanese approval of Simponi for the treatment of ulcerative colitis

FDA grants orphan drug designation to NK-012